BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 36042365)

  • 21. Mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia: a report from the Italian AIEOP study group.
    Bresolin S; De Filippi P; Vendemini F; D'Alia M; Zecca M; Meyer LH; Danesino C; Locatelli F; Masetti R; Basso G; Te Kronnie G
    Oncotarget; 2016 May; 7(20):28914-9. PubMed ID: 26980750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia.
    Sakaguchi H; Muramatsu H; Okuno Y; Makishima H; Xu Y; Furukawa-Hibi Y; Wang X; Narita A; Yoshida K; Shiraishi Y; Doisaki S; Yoshida N; Hama A; Takahashi Y; Yamada K; Miyano S; Ogawa S; Maciejewski JP; Kojima S
    PLoS One; 2015; 10(12):e0145394. PubMed ID: 26720758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.
    Yoshida N; Doisaki S; Kojima S
    Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA fingerprints in juvenile myelomonocytic leukemia (JMML) identified miR-150-5p as a tumor suppressor and potential target for treatment.
    Leoncini PP; Bertaina A; Papaioannou D; Flotho C; Masetti R; Bresolin S; Menna G; Santoro N; Zecca M; Basso G; Nigita G; Veneziano D; Pagotto S; D'Ovidio K; Rota R; Dorrance A; Croce CM; Niemeyer C; Locatelli F; Garzon R
    Oncotarget; 2016 Aug; 7(34):55395-55408. PubMed ID: 27447965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RAS pathway mutations in juvenile myelomonocytic leukemia.
    Emanuel PD
    Acta Haematol; 2008; 119(4):207-11. PubMed ID: 18566538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of Gene Mutation and Clinical Characteristics in 19 Children with Juvenile Myelomonocytic Leukemia].
    Weng KZ; Zheng YZ; Zhuang SQ; Chen HY; LE SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1811-1818. PubMed ID: 33283703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
    Chang TY; Dvorak CC; Loh ML
    Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Juvenile myelomonocytic leukemia (JMML): recent advances in molecular pathogenesis and treatment].
    Sakashita K
    Rinsho Ketsueki; 2016 Feb; 57(2):137-46. PubMed ID: 26935631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Juvenile myelomonocytic leukemia with t(3;5)(q25;q35), Auer rods and marked myelodysplasia.
    Li W; Cooley LD; August K
    Pathol Res Pract; 2018 Jun; 214(6):919-923. PubMed ID: 29496305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.
    Stieglitz E; Troup CB; Gelston LC; Haliburton J; Chow ED; Yu KB; Akutagawa J; Taylor-Weiner AN; Liu YL; Wang YD; Beckman K; Emanuel PD; Braun BS; Abate A; Gerbing RB; Alonzo TA; Loh ML
    Blood; 2015 Jan; 125(3):516-24. PubMed ID: 25395418
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantification of granulocyte-macrophage colony-stimulating factor hypersensitivity in juvenile myelomonocytic leukemia by 3H-thymidine assay.
    Tanaka M; Takahashi Y; Xu Y; Yoshida N; Yoshimi A; Villalobos IB; Hama A; Nishio N; Hidaka H; Wang Y; Yagasaki H; Kojima S
    Leuk Res; 2008 Jul; 32(7):1036-42. PubMed ID: 18164384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial.
    Niemeyer CM; Flotho C; Lipka DB; Starý J; Rössig C; Baruchel A; Klingebiel T; Micalizzi C; Michel G; Nysom K; Rives S; Schmugge Liner M; Zecca M; Schönung M; Baumann I; Nöllke P; Benettaib B; Biserna N; Poon J; Simcock M; Patturajan M; Menezes D; Gaudy A; van den Heuvel-Eibrink MM; Locatelli F
    Blood Adv; 2021 Jul; 5(14):2901-2908. PubMed ID: 34297046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD14/16 monocyte profiling in juvenile myelomonocytic leukemia.
    Gadgeel M; Bagla S; Buck S; Shamoun M; Ravindranath Y
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28555. PubMed ID: 32648963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole Genome MBD-seq reveals different CpG methylation patterns in Azacytidine-treated Juvenile Myelomonocytic Leukaemia (JMML) patients.
    Leoncini PP; Vitullo P; Di Florio F; Tocco V; Cefalo MG; Pitisci A; Girardi K; Niemeyer C; Locatelli F; Bertaina A
    Br J Haematol; 2018 Sep; 182(6):909-912. PubMed ID: 28771681
    [No Abstract]   [Full Text] [Related]  

  • 35. Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia.
    Pérez B; Kosmider O; Cassinat B; Renneville A; Lachenaud J; Kaltenbach S; Bertrand Y; Baruchel A; Chomienne C; Fontenay M; Preudhomme C; Cavé H
    Br J Haematol; 2010 Dec; 151(5):460-8. PubMed ID: 20955399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients.
    Coppe A; Nogara L; Pizzuto MS; Cani A; Cesaro S; Masetti R; Locatelli F; Te Kronnie G; Basso G; Bortoluzzi S; Bresolin S
    Hum Mutat; 2018 Apr; 39(4):579-587. PubMed ID: 29316027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.
    De Filippi P; Zecca M; Novara F; Lisini D; Maserati E; Pasquali F; Rosti V; Carlo-Stella C; Zavras N; Cagioni C; Zuffardi O; Pagliara D; Danesino C; Locatelli F
    Pediatr Blood Cancer; 2012 Sep; 59(3):580-2. PubMed ID: 22183880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. After 95 years, it's time to eRASe JMML.
    Meynier S; Rieux-Laucat F
    Blood Rev; 2020 Sep; 43():100652. PubMed ID: 31980238
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.
    Kim HS; Lee JW; Kang D; Yu H; Kim Y; Kang H; Lee JM; Ahn A; Cho B; Kim S; Chung NG; Kim Y; Kim M
    Br J Haematol; 2021 Dec; 195(5):748-756. PubMed ID: 34590720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutation analysis of the BRAF oncogene in juvenile myelomonocytic leukemia.
    de Vries AC; Stam RW; Kratz CP; Zenker M; Niemeyer CM; van den Heuvel-Eibrink MM;
    Haematologica; 2007 Nov; 92(11):1574-5. PubMed ID: 18024410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.